Molecular origins of lung cancer: prospects for personalized prevention and therapy.
暂无分享,去创建一个
Kwok-Kin Wong | R. Herbst | D. Carbone | D. Camidge | E. Haura | F. Johnson | A. Chiappori | K. Reckamp | Kwok-kin Wong | D. Camidge
[1] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[2] Curtis C. Harris,et al. Microenvironmental modulation of asymmetric cell division in human lung cancer cells , 2010, Proceedings of the National Academy of Sciences.
[3] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[4] A. Lokshin,et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. , 2010, Cancer research.
[5] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[6] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[7] Hua Yu,et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.
[8] Kwok-Kin Wong,et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition , 2009, Proceedings of the National Academy of Sciences.
[9] J. Lee,et al. Snail Promotes CXCR2 LigandDependent Tumor Progression in NonSmall Cell Lung Carcinoma , 2009, Clinical Cancer Research.
[10] A. Gualberto,et al. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. , 2009, Current drug targets.
[11] Alexander Pertsemlidis,et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.
[12] Y. Ishikawa,et al. A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.
[13] S. Narumiya,et al. Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator–Activated Receptor γ , 2008, Cancer Prevention Research.
[14] Steven Piantadosi,et al. DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.
[15] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[16] N. Donato,et al. Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects , 2007, Clinical Cancer Research.
[17] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[18] Y. Fukami,et al. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells , 2006, Journal of Cell Science.
[19] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.